<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;table cellspacing="0" cellpadding="2" border="0" summary="This table shows the date, time, and location of the meeting" style="width: 601px; height: 110px;" id="schedule"&gt;     &lt;tbody&gt;         &lt;tr&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" style="WIDTH: 71px" id="a1"&gt;Center&lt;/th&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" style="WIDTH: 158px" id="a2"&gt;Date&lt;/th&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" style="WIDTH: 172px" id="a3"&gt;Time&lt;/th&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" style="WIDTH: 238px" id="a4"&gt;Location&lt;/th&gt;         &lt;/tr&gt;         &lt;tr&gt;             &lt;td valign="top" headers="a1" style="WIDTH: 71px; HEIGHT: 74px"&gt;CDER&lt;/td&gt;             &lt;td valign="top" headers="a2" style="WIDTH: 158px; HEIGHT: 74px"&gt;July 19,  2011&lt;br /&gt;             &amp;nbsp;&lt;/td&gt;             &lt;td valign="top" headers="a3" style="WIDTH: 172px; HEIGHT: 74px"&gt;8:00 a.m. to 5:00  p.m.&lt;/td&gt;             &lt;td valign="top" headers="a4" style="WIDTH: 238px; HEIGHT: 75px"&gt;Hilton Washington DC/Silver Spring&lt;br /&gt;             The Ballrooms&lt;br /&gt;             8727 Colesville Road&lt;br /&gt;             Silver Spring, Maryland&lt;/td&gt;         &lt;/tr&gt;     &lt;/tbody&gt; &lt;/table&gt;&lt;/p&gt; &lt;p&gt;&lt;b&gt;Agenda&lt;/b&gt;&lt;/p&gt; &lt;p&gt;On July 19, 2011, the committee will discuss new drug application (NDA) 202293 dapagliflozin, manufactured by Bristol-Myers Squibb and AstraZeneca.  Dapagliflozin is the first drug in the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.&lt;/p&gt; &lt;p&gt;&lt;b&gt;Meeting Materials&lt;/b&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;FDA intends to make the complete background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Background material:&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt;     &lt;li&gt;&lt;a target="" href="[!--$wcmUrl('link','UCM252891')--]"&gt;2011 Meeting Materials, Endocrinologic and Metabolic Drugs Advisory  Committee&lt;/a&gt;&lt;/li&gt; &lt;/ul&gt; &lt;div style="TEXT-ALIGN: left"&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;&lt;b&gt;Public Participation Information&lt;/b&gt;&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;Interested persons may present data, information,  or views, orally or in writing, on issues pending before the committee.&lt;/div&gt; &lt;ul&gt;     &lt;li&gt;Written submissions may be made to the contact person on or before July 5, 2011.&lt;/li&gt;     &lt;li&gt;Oral presentations from the public will be scheduled between approximately 1:00 p.m. to 2:00 p.m., on July 19, 2011.  Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before June 24, 2011&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;Time allotted for each presentation may be limited.  If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled  open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.  The contact person will notify interested persons regarding their request to speak by June 27, 2011.&lt;/p&gt; &lt;div style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;&lt;b&gt;Contact Information&lt;/b&gt;&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;Paul Tran, R.Ph.&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;Center for Drug Evaluation and Research&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;Food and Drug Administration&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;10903 New Hampshire Avenue&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;WO31-2417&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;Silver Spring, MD&amp;nbsp;20993&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;Phone: 301-796-9001&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;Fax: 301-847-8533&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;E-mail: &lt;a href="mailto:EMDAC@fda.hhs.gov"&gt;EMDAC@fda.hhs.gov&lt;/a&gt;&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;FDA Advisory Committee Information Line&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;1-800-741-8138&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;(301-443-0572 in the Washington DC area)&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:WordDocument&gt;
  &lt;w:View&gt;Normal&lt;/w:View&gt;
  &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;
  &lt;w:PunctuationKerning /&gt;
  &lt;w:ValidateAgainstSchemas /&gt;
  &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;
  &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;
  &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;
  &lt;w:Compatibility&gt;
   &lt;w:BreakWrappedTables /&gt;
   &lt;w:SnapToGridInCell /&gt;
   &lt;w:WrapTextWithPunct /&gt;
   &lt;w:UseAsianBreakRules /&gt;
   &lt;w:DontGrowAutofit /&gt;
  &lt;/w:Compatibility&gt;
  &lt;w:BrowserLevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;
 &lt;/w:WordDocument&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:LatentStyles DefLockedState="false" LatentStyleCount="156"&gt;
 &lt;/w:LatentStyles&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt;
&lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0pt 5.4pt 0pt 5.4pt;
	mso-para-margin:0pt;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
&lt;/style&gt;
&lt;![endif]--&gt;- follow the prompts to the desired center or product area&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;Please call the Information Line for up-to-date  information on this meeting.&lt;/div&gt; &lt;div style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/div&gt; &lt;p&gt;A notice in the Federal Register about last minute modifications that impact  a previously announced advisory committee meeting cannot always be published  quickly enough to provide timely notice. Therefore, you should always check the  agency&amp;rsquo;s Website and call the appropriate advisory committee hot line/phone line  to learn about possible modifications before coming to the meeting.&lt;/p&gt; &lt;p&gt;FDA intends to make background material available to the public no later than  2 business days before the meeting. If FDA is unable to post the background  material on its Web site prior to the meeting, the background material will be  made publicly available at the location of the advisory committee meeting, and  the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt; &lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the  agency is not responsible for providing access to electrical outlets. FDA  welcomes the attendance of the public at its advisory committee meetings and  will make every effort to accommodate persons with physical disabilities or  special needs. If you require special accommodations due to a disability, please  contact Paul Tran at (301) 796-9001 at least 7 days in advance of the meeting.  FDA is committed to the orderly conduct of its advisory committee meetings.&lt;/p&gt; &lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5  U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
